Symposium on globalisation

The Alumni Association of the Lancaster University Management School organised a mini symposium on globalisation, in New Delhi on January 17th 2004. The symposium was based on a collection of essays titled " Making Globalisation Good" edited by John Dunning (Oxford University Press, 2003: Paperback Edition 2004). The theme of the book- moral challenges posed by globalisation, is addressed by a constellation of academics, politicians, business leaders and religious leaders. The contributors to the volume include the Nobel Laureate Joseph Stiglitz, Dame Shirley Williams, Chief Rabbi Jonathan Sacks, Khurshid Ahmad of the Islamic Foundation and Gordon Brown. John Dunning's incisive essay on the moral imperatives of global capitalism sets the stage for the varied and extensive discussion of the main theme of the book. The New Delhi Symposium with commentaries on the book by three of India's eminent commentators and analysts of issues of globalisation provides an Indian perspective on the issues discussed in John Dunning's book. This discussion paper presents an edited version of the introductory remarks by John Dunning and comments by N.K. Singh, Professor Narasimha and Ashok Desai.

Diabetes in 2007 - What are the promises & challenges?

No Abstrac

Orally active insulin mimics: where do we stand now?

The war against diabetes through the development of new drugs is an ongoing continuous process to counter the alarming global increase in the prevalence of diabetes and its complications, particularly in developing countries like India. Unfortunately, the speed with which our knowledge of diabetes and its effects is expanding is not matched by the availability of new drugs. Following the identification of the insulin receptor (IR), its intrinsic kinase activity and molecular cloning, many studies have looked at IR as an ideal drug target. This review summarizes in brief the latest advancements in this field with particular reference to the current situation in respect of the development of orally active insulin mimetics in the treatment of type 2 diabetes